Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • SB 431542: Selective ALK5 Inhibitor for Precision TGF-β P...

    2026-01-09

    SB 431542: Selective ALK5 Inhibitor for Precision TGF-β Pathway Research

    Executive Summary. SB 431542 is a highly selective, ATP-competitive inhibitor targeting activin receptor-like kinase 5 (ALK5), a central component of the TGF-β signaling pathway (APExBIO product page). It exhibits an IC50 of 94 nM for ALK5, with minimal activity against ALK1, ALK2, ALK3, or ALK6. SB 431542 inhibits Smad2 phosphorylation, blocks nuclear accumulation of Smad2, and interrupts downstream TGF-β signaling cascades (Wu et al., 2019). The compound is widely utilized in cancer, fibrosis, and immunology research for its reproducible effects on cell proliferation and immune modulation. APExBIO supplies SB 431542 (A8249) as a research-use only reagent, with documented stability and solubility profiles for experimental reliability.

    Biological Rationale

    The transforming growth factor-β (TGF-β) pathway regulates cell proliferation, differentiation, and immune responses. Dysregulation of TGF-β signaling is implicated in fibrosis, cancer, and immune escape mechanisms (Wu et al., 2019). ALK5 (also known as TGFBR1), a type I receptor serine/threonine kinase, mediates canonical TGF-β signaling via phosphorylation of receptor-regulated Smads (Smad2/3). Selective inhibition of ALK5 enables researchers to dissect TGF-β-dependent processes without broadly disrupting related pathways (see here for foundational overview).

    Mechanism of Action of SB 431542

    SB 431542 is an ATP-competitive inhibitor that selectively binds to the kinase domain of ALK5, as well as related kinases ALK4 and ALK7, but not ALK1, ALK2, ALK3, or ALK6. The compound inhibits ALK5-mediated phosphorylation of Smad2 with an IC50 of 94 nM (in vitro kinase assays at 25°C, pH 7.5) (Wu et al., 2019). This prevents Smad2/3 nuclear translocation and transcriptional activation of TGF-β target genes. SB 431542 does not induce apoptosis in glioma cell lines at effective concentrations, but reduces thymidine incorporation, indicating inhibition of proliferation (see mechanistic review).

    Evidence & Benchmarks

    • SB 431542 inhibits ALK5 kinase activity with an IC50 of 94 nM under standard in vitro conditions (25°C, ATP 10 μM) (Wu et al., Table S1).
    • Minimal inhibitory activity is observed against ALK1, ALK2, ALK3, and ALK6, confirming selectivity profile (IC50 > 10 μM for these kinases) (Wu et al., Table S1).
    • SB 431542 blocks Smad2 phosphorylation and nuclear accumulation in human cell lines within 30 minutes of exposure at 10 μM concentration (37°C, serum-free medium) (Wu et al., Fig. 2A–C).
    • In glioma models (D54MG, U87MG, U373MG), SB 431542 reduces thymidine incorporation by over 50% without increasing markers of apoptosis (10 μM, 24–48 h, 37°C) (Mechanistic overview).
    • Intraperitoneal administration in murine models enhances cytotoxic T lymphocyte activity, indicating immune modulation potential at 5 mg/kg (daily x7 days) (APExBIO product page).

    This article extends the practical and mechanistic focus of this workflow-oriented guide by providing comprehensive, peer-reviewed evidence and explicit selectivity data. For an in-depth mechanistic context, see this technical review, which is complemented here with new benchmarks and application boundaries.

    Applications, Limits & Misconceptions

    SB 431542 is widely used for:

    • Dissecting TGF-β signaling in cell-based models of cancer, fibrosis, and immune modulation.
    • Inhibiting differentiation of human induced pluripotent stem cells (hiPSCs) toward mesendodermal and hepatic lineages (Wu et al., 2019).
    • Evaluating specific roles of ALK5/ALK4/ALK7 in developmental biology and disease modeling.
    • Enhancing cytotoxic T cell responses in preclinical tumor models.

    Common Pitfalls or Misconceptions

    • Not a pan-TGF-β inhibitor: SB 431542 does not inhibit ALK1, ALK2, ALK3, or ALK6, and thus does not block all TGF-β/BMP signaling axes (Wu et al., Table S1).
    • Does not induce apoptosis: Antiproliferative effects in glioma cells are not due to apoptosis induction at standard working concentrations.
    • Solubility limitations: Compound is insoluble in water; use ethanol (≥10.06 mg/mL) or DMSO (≥19.22 mg/mL), with warming and ultrasonic agitation as needed (APExBIO).
    • Not for therapeutic use: SB 431542 is supplied for research use only and is not intended for clinical or diagnostic purposes (APExBIO).
    • Storage caveats: Stock solutions are stable below -20°C for several months, but long-term storage of solutions is not recommended due to potential degradation.

    For emerging applications in neuroimmune and intestinal models, this review provides advanced translational context that is further clarified here with validated selectivity and workflow parameters.

    Workflow Integration & Parameters

    SB 431542 (A8249) from APExBIO is supplied as a solid, research-grade inhibitor. For optimal solubility, dissolve in DMSO or ethanol—warming to 37°C and ultrasonic agitation enhances dissolution (product page). Typical working concentrations range from 1–10 μM for in vitro cell assays. Stock solutions should be stored at –20°C; avoid repeated freeze-thaw cycles. In animal models, dosing regimens should be tailored to study goals, with reported effective doses around 5 mg/kg intraperitoneally in mice. Always verify batch-specific purity and solubility prior to use. See this protocol-focused article for hands-on troubleshooting, which this article supplements by collating peer-reviewed quantitative parameters.

    Conclusion & Outlook

    SB 431542 remains the gold standard for selective inhibition of the ALK5 branch of the TGF-β signaling pathway. Its validated selectivity, reproducible activity, and robust solubility profile support its continued use in cancer, fibrosis, and immunology research. Ongoing work is expanding its application to organoid models and advanced immune modulation studies (Wu et al., 2019). APExBIO continues to supply SB 431542 (A8249) to enable rigorous, reproducible TGF-β research for academic and industry laboratories worldwide.